Open access
Oct 2026
Long-term Benefits of Mirikizumab on Patient-Reported Outcomes in Individuals with Crohn's Disease: 2-Year Results from the VIVID-2 Extension Study.
BACKGROUND Mirikizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated clinical efficacy in Crohn's disease (CD), improving symptoms and quality of life (QoL) over one year in the VIVID-1 trial. This analysis from the VIVID-2 open-label extension evaluated its long-term impact on CD symptoms and QoL at two year...
Min-Hu Chen, Ailsa L. Hart, A. Vadhariya et al.
· Clinical and Translational G... · 0 citations